A new study led by investigators from the UCLA Health Jonsson Comprehensive Cancer Center has demonstrated a new, non-invasive imaging technique can accurately detect clear-cell renal cell carcinoma, ...
In this video, Elizabeth Plimack, MD, MS, FASCO, Deputy Director at Fox Chase Cancer Center, discusses current treatments for ...
"Imaging using [⁸⁹Zr]Zr-girentuximab has the potential to change clinical practice in renal cell carcinoma," write the study authors. HealthDay News — ⁸⁹Zr-labeled monoclonal antibody ...
ITM-94, a gallium-68-radiolabeled PET imaging agent, targets carbonic anhydrase IX, crucial in tumor growth and metastasis. The FDA's fast track designation aims to expedite ITM-94's development for ...
Efficacy of second line (2L) treatment with tivozanib (Tivo) as monotherapy or with nivolumab (Nivo) in patients (pts) with metastatic renal cell carcinoma (mRCC) previously treated with an immune ...
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for ...
In risk groups defined by American Urologic Association criteria, recurrences were reported in 8.9% of patients of the low-risk group, 11% of patients in the intermediate-risk group, 22% of those in ...
In a recent study, mean sensitivity was 85.5% and specificity 87% for detection of clear-cell renal cell carcinoma. (HealthDay News) — ⁸⁹Zr-labeled monoclonal antibody ([⁸⁹Zr]Zr-girentuximab) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results